World News

Eritrea eliminates trachoma as a public health problem, marking a milestone in the fight against preventable blindness

Posted by: Semere Asmelash

Date: Tuesday, 17 November 2026


Eritrea eliminates trachoma as a public health problem, marking a milestone in the fight against preventable blindness

17 November 2026

“Eritrea’s elimination of trachoma as a public health problem is a remarkable achievement and a powerful example of what sustained country leadership and long-term partnership can accomplish. Pfizer is proud to have supported Eritrea’s progress through our donation of more than 3 million azithromycin doses in country since 2009 and, more broadly, our longstanding partnership with the International Trachoma Initiative. We congratulate the Government of Eritrea, health workers and communities whose dedication helped protect millions of people from this preventable cause of blindness.”

-Darren Back, Vice President, Global Health Investments, Pfizer

Mass drug administration (MDA) began in 2011 and continued through 2022. Trained community drug distributors played a critical role in ensuring eligible residents could access treatment, visiting households to offer antibiotics and conducting follow-up visits to reach people who were absent during initial distribution efforts.

The impact of these sustained efforts was reflected in a series of surveys conducted between 2014 and 2022. Results confirmed that the prevalence of trachomatous inflammation—follicular (TF) among children aged 1-9 years had fallen below the WHO elimination threshold of 5% in all 25 treated districts. Tropical Data, a global initiative supported by ITI, provided technical support for 64 trachoma surveys in Eritrea, including 15 baseline, 23 impact and 26 surveillance surveys, generating critical data to inform program decision-making and azithromycin allocation. 

In Adi Quala, where TF prevalence subsequently rose above the elimination threshold following the initial rounds of treatment, the national program responded by resuming MDA. A 2024 surveillance survey confirmed that prevalence remained below 5% following the additional treatment.

Sustaining progress toward global elimination

Beyond antibiotic treatment, Eritrea expanded access to TT surgery and implemented community-based hygiene and sanitation initiatives. The country established 34 TT surgery centers and trained more than 1,000 case finders to identify and refer people for care. By July 2025, 93% of Eritrea's 2,830 villages had been certified open defecation free. To sustain its elimination status, Eritrea plans to continue monitoring trachoma through its routine health information system, providing TT surgery and conducting periodic surveillance surveys in selected districts.

Eritrea's achievement contributes to the global effort to eliminate trachoma as a public health problem by 2030, as outlined in the WHO's neglected tropical diseases road map. As of March 2026, an estimated 92 million people were living in areas where trachoma remained endemic and interventions were still needed globally—a 94% reduction from the global number estimated to be at risk in 2002.

Through its partnership with Pfizer, ITI supports national trachoma programs by facilitating access to donated azithromycin and working with health ministries and partners to strengthen distribution. 

“Eritrea's success demonstrates the impact of national commitment and access to donated azithromycin in the global effort to eliminate trachoma. Alongside Pfizer, ITI worked with Eritrea and its partners to ensure that more than 3 million donated azithromycin treatments reached the people who needed it. We congratulate Eritrea on this tremendous milestone and recognize the health workers, community drug distributors and partners whose dedication made it possible.”

— PJ Hooper, Director, International Trachoma Initiative

About the International Trachoma Initiative

For more than 25 years, the International Trachoma Initiative (ITI), a program of the Task Force for Global Health, has worked as part of a global network of partners, health ministries, and communities to ensure life-saving donated medicines reach the people who need them most.

As a trusted steward of azithromycin donations, ITI brings together partners across countries and sectors to support the elimination of trachoma as a public health problem and to advance child survival. Through strong partnerships, country-led approaches, and a commitment to generating, sharing, and using high-quality data, ITI helps ensure medicines are delivered safely, equitably, and at the right time — earning trust at the community level and strengthening health systems for the long term.
The World Health Organization (WHO) validated Eritrea's elimination of trachoma as a public health problem on November 16, 2026, marking it as the 11th country in the WHO African Region and the 34th globally to reach this milestone. More details can be found in the WHO News Release. 

Permutation Law - ሕጊ ምልውዋጥ Math

Dehai Events